Prognostic value of MAGE-A and NY-ESO-1 expression in pharyngeal cancer.
BACKGROUND
The prognostic value of cancer testis antigens in pharyngeal cancer is understudied.


METHODS
We recruited 90 patients who were treated for pharyngeal cancer. Monoclonal antibodies 57B and B9.8.1.1 were used for detection of MAGE-A and NY-ESO-1 genes.


RESULTS
MAGE-A and NY-ESO-1 gene products were detectable in 70.0% and 33.3% of pharyngeal tumors, respectively. No correlation was established between MAGE-A and NY-ESO-1 expression and TNM staging at presentation. Survival analysis showed a trend toward a shorter 5-year disease-free survival in the group of patients with MAGE-A-positive tumors (log-rank test, p = .122). In contrast, a trend toward a prolonged 5-year disease-free survival was observed in the group of patients with NY-ESO-1-positive tumors (log-rank test, p = .219).


CONCLUSIONS
In a large population of patients with pharyngeal cancer and available 5-year survival data, prognosis tended to be poorer with MAGE-A expression and better with NY-ESO-1 expression, but the correlations did not reach statistical significance.
Pastorcic-Grgic
Marija
M
Department of Head and Neck Surgery, University Hospital for Tumors, Zagreb, Croatia. marija_pastgrgic@yahoo.com
Sarcevic
Bozena
B
Dosen
Danijel
D
Juretic
Antonio
A
Spagnoli
Giulio C
GC
Grgic
Marko
M
D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000235:genetics / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000097:blood*; D001707:Biopsy, Needle; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D016009:Chi-Square Distribution; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D007822:Laryngeal Neoplasms / Q000235:genetics* / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis / Q000235:genetics / Q000378:metabolism*; D009367:Neoplasm Staging; D010446:Peptide Fragments / Q000235:genetics / Q000378:metabolism*; D011379:Prognosis; D012189:Retrospective Studies; D018570:Risk Assessment; D015996:Survival Rate
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C095204:MAGEA4 protein, human; D009363:Neoplasm Proteins; D010446:Peptide Fragments; C522785:peptide NY-ESO-1 157-170